Electra Therapeutics, Inc. today announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share.
Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share.
$2.5 million grant supports clinical trial activation and patient screening efforts for precision medicine approach targeting LRRK2-driven Parkinson’s disease at four clinical sites in Israel
Targeting clinically validated pathways to enable patients to achieve freedom from migraine
Recludix today announced preclinical data for REX-8756, an oral, potent and selective STAT6 inhibitor, is being presented at two upcoming scientific congresses.
Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Veteran biopharma leader joins to help lead Kyverna’s next phase of commercial growth
